WO2022094025A1 - Angiotensin-1-7 for the treatment of covid-19 - Google Patents
Angiotensin-1-7 for the treatment of covid-19 Download PDFInfo
- Publication number
- WO2022094025A1 WO2022094025A1 PCT/US2021/056974 US2021056974W WO2022094025A1 WO 2022094025 A1 WO2022094025 A1 WO 2022094025A1 US 2021056974 W US2021056974 W US 2021056974W WO 2022094025 A1 WO2022094025 A1 WO 2022094025A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- subject
- day
- sars
- composition
- Prior art date
Links
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 title claims abstract description 19
- 108010021281 angiotensin I (1-7) Proteins 0.000 title claims abstract description 13
- 102400000347 Angiotensin 1-7 Human genes 0.000 title claims abstract description 9
- 208000025721 COVID-19 Diseases 0.000 title claims description 26
- 238000011282 treatment Methods 0.000 title description 21
- 238000000034 method Methods 0.000 claims abstract description 47
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 238000001802 infusion Methods 0.000 claims abstract description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 32
- 229920001184 polypeptide Polymers 0.000 claims abstract description 30
- 241000315672 SARS coronavirus Species 0.000 claims abstract description 18
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 16
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 150000001413 amino acids Chemical class 0.000 claims abstract description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 30
- 239000001301 oxygen Substances 0.000 claims description 30
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 230000009429 distress Effects 0.000 claims description 14
- 206010013975 Dyspnoeas Diseases 0.000 claims description 11
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 11
- 206010038687 Respiratory distress Diseases 0.000 claims description 11
- 102400000345 Angiotensin-2 Human genes 0.000 claims description 10
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 10
- 229950006323 angiotensin ii Drugs 0.000 claims description 10
- 230000006870 function Effects 0.000 claims description 10
- 210000004789 organ system Anatomy 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 9
- 208000000059 Dyspnea Diseases 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000013220 shortness of breath Diseases 0.000 claims description 7
- 230000015271 coagulation Effects 0.000 claims description 6
- 238000005345 coagulation Methods 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 230000003925 brain function Effects 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 230000003907 kidney function Effects 0.000 claims description 4
- 230000004199 lung function Effects 0.000 claims description 4
- DUEUCUPESSMDMI-VVKHCXNMSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 DUEUCUPESSMDMI-VVKHCXNMSA-N 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 230000004900 autophagic degradation Effects 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 230000004217 heart function Effects 0.000 claims description 3
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 3
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 description 42
- 229940068196 placebo Drugs 0.000 description 32
- 239000000902 placebo Substances 0.000 description 32
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 238000005399 mechanical ventilation Methods 0.000 description 12
- 238000009423 ventilation Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000009467 reduction Effects 0.000 description 8
- 201000004193 respiratory failure Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000002627 tracheal intubation Methods 0.000 description 8
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 7
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 7
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 230000000241 respiratory effect Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 102000003951 Erythropoietin Human genes 0.000 description 6
- 108090000394 Erythropoietin Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000153 supplemental effect Effects 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
- 230000036387 respiratory rate Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 208000004852 Lung Injury Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000015925 Proto-oncogene Mas Human genes 0.000 description 3
- 108050004181 Proto-oncogene Mas Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 229960003121 arginine Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 231100000515 lung injury Toxicity 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002640 oxygen therapy Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000005526 vasoconstrictor agent Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 229960003589 arginine hydrochloride Drugs 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000005182 global health Effects 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- -1 mono- Chemical class 0.000 description 2
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000036593 pulmonary vascular resistance Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000003519 ventilatory effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000001838 Angiotensin II receptor type 1 Human genes 0.000 description 1
- 108050009086 Angiotensin II receptor type 1 Proteins 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241001069765 Fridericia <angiosperm> Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010271 Heart Block Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102400000569 Myeloperoxidase Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000029464 Pulmonary infiltrates Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 229910003798 SPO2 Inorganic materials 0.000 description 1
- 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000010285 Ventilator-Induced Lung Injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 229940124977 antiviral medication Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000013504 emergency use authorization Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000003027 hypercoagulation Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000013187 longer-term treatment Methods 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005074 megakaryoblast Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000009512 pharmaceutical packaging Methods 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- the subject is a human subject.
- the method improves lung function, bone marrow function, kidney function, coagulation parameters, brain function, and/or heart function; and/or the method reduces local organ system production of angiotensin II,
- the disclosure provides methods for treating a severe acute respiratory syndrome (SARS) coronavirus infection, comprising administering to a subject with a SARS coronavirus infection a composition comprising an amount effective to treat the infection of a polypeptide consisting of at least 4 consecutive amino acids of angiotensin 1-7 (A(l-7)) [Asp-Arg-Val-Tyr-Iie-His-Pro (SEQ ID NO: 1)] or a pharmaceutically’ acceptable salt thereof, wherein the administering comprises continuous infusion of the composition for at least 7 consecutive days.
- SARS severe acute respiratory syndrome
- the SARS coronavirus infection comprises SARS-CoV or SARS CO VID-19. In another embodiment, the SARS coronavirus infection comprises SARS COVID-19.
- composition comprises one or more polypeptides consisting of the amino acid sequence:
- Val-Tyr-Ile-His-Pro (SEQ ID NO:4) A(3-7).
- the administering comprises continuous infusion of the composition for at least 8, 9, 10, 11, 12, 13, 14, or more consecutive days. In another embodiment the administering comprises continuous intravenous infusion of the polypeptide for at least 14 consecutive days.
- the polypeptide is administered at a concentration of between about 0.05 ug/mg (w/w) and about 500 ug/mg (w/w). In another embodiment, the polypeptide is administered at a concentration of between about 1 ug/mg (w/w) and about 100 ug/mg (w/w). In various further embodiments, the polypeptide is continuously infused at an infusion rate of at least 6.25 ng/kg/min (9 ug/kg/day); at least 25 ng/kg/min (36 ug/kg/day); at least 42 ng/kg/min (60.48 ug/kg/day), or at least 62.5 ng/kg/min (90 ug/kg/day).
- Symptoms and features characteristic of SARS coronavirus infection that the methods may be used to treat or limit include, but are not limited to shortness of breath, reduced oxygen saturation, (SPO2), respiratory distress requiring oxygen, severe acute respiratory' distress, acute respiratory' distress syndrome (ARDS), need for hospitalization, need for intubation or other mechanical ventilation, reduction in need for subject stay in the intensive care unit, reduction in positive end expiratory pressure (PEEP), respiratory failure, widespread inflammation and damage to multiple organ systems including the heart, kidney, liver, lungs, brain, and bone marrow; multiple organ failure, and death.
- SPO2 reduced oxygen saturation
- ARDS acute respiratory' distress syndrome
- PEEP positive end expiratory pressure
- the subject is a human subject that is hospitalized.
- the subject has one or both of shortness of breath and respiratory distress requiring oxygen; and/or the subject has severe acute respiratory distress.
- the subject may be any suitable subject that may be infected with a SARS coronavirus.
- the subject is a human subject.
- the methods result in one or more of (compared to a subject with a SARS coronavirus infection who receives no treatment, and/or compared to previous symptoms of the subject prior to treatment): o Improved lung function: As used herein, ‘"improved lung function” means one or more of increased oxygenation of the blood, reduced pulmonary infiltrates, reduced dyspnea, reduced cough, reduced pain, reduced inflammation, reduced shortness of breath, reduced death rate due (at least in part) to lung complications, reduced time on ventilator, reduced time in ICU due (at least in part) to lung complications, reduced time in hospital, and/or reduced return visits to health care providers both in patient and hospitalized; o Improved bone marrow function: As used herein, “improved bone marrow function” means one or more of reduction of anemia, reduction of thrombocytopenia, reduction of lymphopeni
- Improved coagulation parameters means one or more of reduced embolism, reduced embolic disease (time of onset, extent, duration), normalized coagulation, and/or reduced coagulopathy; o Improved brain function: As used herein, ‘Improved brain function” means one or more of improved cognition, reduced fuzzy brain syndrome, reduced headaches, reduced lassitude and irritability, reduced somnolence, improved attention span, reduced loss of smell and/or taste, reduced stroke, reduced inflammation, and/or reduced delirium ; and/or o Improved heart function in the subject: As used herein, “Improved brain function” means one or more of reduced incidence and/or severity of heart attack, reduced incidence and/or duration of arrhythmias, reduced congestive heart failure, improved cardiac output, reduced incidence and/or duration of va
- reference to the polypeptide includes salts of the polypeptide.
- Suitable acids which are capable of forming salts with the polypeptides include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like; and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid and the like.
- the polypeptide can further be derivatized to provide enhanced half-life, for example, by linking to polyethylene glycol.
- the peptides or salts thereof may comprise L-amino acids. D-amino acids (which are resistant to L-amino acid-specific proteases in vivo) to convey special properties as deemed appropriate.
- compositions may comprise other components as deemed appropriate by attending medical personnel.
- the compositions may comprise one or more (a) a lyoprotectant; (b) a surfactant; (c) a bulking agent; (d) a tonicity adjusting agent; (e) a stabilizer; (f) a preservative and/or (g) a buffer.
- the buffer in the composition is a Tris buffer, a histidine buffer, a phosphate buffer, a citrate buffer or an acetate buffer.
- the composition may comprise a lyoprotectant, e.g. sucrose, sorbitol or trehalose.
- the composition may comprise a preservative e.g. benzalkonium chloride, benzethonium, chlorohexidme, phenol, m-cresol, benzyl alcohol, methylparaben, propylparaben, chlorobutanol, o-cresol, p-cresol, chlorocresol, phenylmercuric nitrate, thimerosal, benzoic acid, and various mixtures thereof.
- the composition may comprise a bulking agent, like glycine .
- the composition may comprise a surfactant e.g., polysorbate-20, polysorbate-40, polysorbate- 60, polysorbate-65, polysorbate-80 polysorbate-85, poloxamer- 188, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trilaurate, sorbitan tristearate, sorbitan trioleaste, or a combination thereof.
- the composition may comprise a tonicity adjusting agent, e.g., a compound that renders the formulation substantially isotonic or isoosmotic with human blood.
- Exemplary tonicity adjusting agents include sucrose, sorbitol, glycine, methionine, mannitol, dextrose, inositol, sodium chloride, arginine and arginine hydrochloride.
- the composition may comprise a stabilizer, e.g., a molecule which, when combined with the polypeptide substantially prevents or reduces chemical and/or physical instability of the polypeptide in lyophilized or liquid form.
- Exemplary stabilizers include sucrose, sorbitol, glycine, inositol, sodium chloride, methionine, arginine, and arginine hydrochloride, paraben, and combinations of methyl paraben and propyl paraben.
- Tire polypeptides may be tire sole active agent in the compositions, or the composition may further comprise one or more other active agents suitable for the desired treatment, including but not limited to anti-viral agents, corticosteroids, anti-coagulants, and agents that affect autophagy (including but not limited to hydroxychloroquine).
- active agents suitable for the desired treatment including but not limited to anti-viral agents, corticosteroids, anti-coagulants, and agents that affect autophagy (including but not limited to hydroxychloroquine).
- Example 1 A Phase 2 Randomized Double-Blinded Placebo Control (i.e. Standard of
- COVID-19 ieads to induced respiratory distress which progresses from SOB requiring hospitalization and supplemental oxygen by nasal cannula, high flow oxygen delivered by a mask with ⁇ 15 liters/mmute of oxygen, BiPAP with a mask that delivers high pressure 100% oxygen at 5 mmHg peak inspiratory pressure, and ultimately to intubation and assisted ventilation with a respirator.
- BiPAP with a mask that delivers high pressure 100% oxygen at 5 mmHg peak inspiratory pressure
- COVID- 19 pre sents an acute and urgent threat to global health security.
- Therapeutic interventions capable of reducing pulmonary distress would reduce the fatality rate, improve long term outcomes, and free up scarce ICU resources.
- Toxicity will be graded according to the NCI-CTCAE Version 5.0 criteria. Limiting toxicities will be considered as any SAE or Grade 3 to 5 toxicity judged to be probably or definitely related to USB002 or any of the predetermined study specific criteria, as determined by the DSMB.
- USB002 should not be administered at the same time with other medications in the line and in some instances may' require a dedicated line however, USB002 can be administered with the following:
- Subjects will be enrolled to the trial once they are diagnosed with COVID-19 and pulmonary distress requiring supplemental oxygen, consent has been obtained from the subjects or their legal representative and eligibility' has been confirmed.
- Baseline laboratory' assessments will be obtained, if not already completed prior to subject consent.
- Baseline data will include time of admission to hospital, ICU, and time of supplemental oxygen therapy, nasal high-flow oxygen therapy, non-invasive mechanical ventilation or mechanical ventilator via intubation initiation. Registration will be performed by the Study Coordinator, the drug will be requested from the pharmacy, and dosing will begin within 6 hours (study Dav 1).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods for treating a severe acute respiratory syndrome (SARS) coronavirus infection are provided, involving administering to a subject with a SARS coronavirus infection a composition including a polypeptide of at least 4 consecutive amino acids of angiotensin 1-7 (A(1-7)) [Asp-Arg-Val-Tyr-Ile-His-Pro (SEQ ID NO:1)] or a pharmaceutically acceptable salt thereof, wherein the administering involves continuous infusion of the composition for at least 4, 5, 6, or 7 consecutive days.
Description
ANGIOTENSIN-1-7 FOR THE TREATMENT OF COVID-19
Cross Reference
This application claims priority to U.S. Provisional Patent Application Serial No.
63/108272. filed October 30, 2020, incorporated by reference herein in its entirety
Federal Funding Statement
This invention was made with government support under Grant No. PR202594 awarded by the Department of Defense. The government has certain rights in the invention.
Sequence Listing Statement:
A computer readable form of the Sequence Listing is filed with this application by electronic submission and is incorporated into this application by reference in its entirety. The Sequence Listing is contained in the file created on October 27, 2021 having the file name “20-1696-WO-SeqList ST25.txt” and is 1 kb in size.
Background
COVID-19 leads to induced respiratory distress which progresses from shortness of breath to requiring hospitalization and supplemental oxygen by nasal cannula, high flow oxygen delivered by a mask with <15 liters/minute of oxygen, BiPAP with a mask that delivers high pressure 100% oxygen at 5 mmHg peak inspiratory pressure, and ultimately to intubation and assisted ventilation with a respirator. With the number of COVID-19 cases in the United States since January of 2020 exceeding all other countries, COVID- 19 presents an acute and urgent threat to global health security . Therapeutic interventions capable of reducing pulmonary distress would reduce the fatality rate, improve long term outcomes, and free up scarce ICU resources.
Summary
In one aspect, the disclosure provides methods for treating a severe acute respiratory syndrome (SARS) coronavirus infection, comprising administering to a subject with a SARS coronavirus infection a composition comprising an amount effective to treat the infection of a polypeptide consisting of at least 4 consecutive amino acids of angiotensin 1-7 (A( 1-7)) [Asp-Arg-Val-Tyr-Ile-His-Pro (SEQ ID NO: 1)] or a pharmaceutically acceptable salt thereof,
wherein the administering comprises continuous infusion of the composition for at least 4, 5, 6. or 7 consecutive days. In one embodiment, the SARS coronavirus infection comprises SARS-CoV or SARS COVID-19. In another embodiment, the composition comprises one or more polypeptides consisting of the ammo acid sequence:
Asp-Arg-Val-Tyr-Ile-His-Pro (SEQ ID NO: 1) A(l-7);
Asp-Arg-Val-Tyr-Ile (SEQ ID NO:2) A(1 -5);
Arg-Val-Tyr-Ile-His-Pro (SEQ ID NO:3) A(2-7); and/or
Val-Tyr-Ile-His-Pro (SEQ ID NO:4) A(3-7).
In another embodiment, the administering comprises continuous intravenous infusion. In a further embodiment, the administering comprises continuous infusion of the composition for at least 8, 9, 10, 11 , 12, 13, 14, or more consecutive days. In various embodiments, the polypeptide is administered at a concentration of between about 0.05 ug/mg (w/w) and about 500 ug/mg (w/w); the polypeptide is administered at a concentration of between about 1 ug/mg (w/w) and about 100 ug/mg (w/w); and/or the polypeptide is continuously infused at an infusion rate of at least 6.25 ng/kg/min (9 ug/kg/day); at least 25 ng/kg/min (36 ug/kg/day); at least 42 ng/kg/min (60.48 ug/kg/day), or at least 62.5 ng/kg/min (90 ug/kg/day).
In one embodiment, the subject is a human subject. In other embodiments, the method improves lung function, bone marrow function, kidney function, coagulation parameters, brain function, and/or heart function; and/or the method reduces local organ system production of angiotensin II,
In various further embodiments, the subject is a human subject that is hospitalized; the subject has one or both of shortness of breath and respiratory distress requiring oxygen; and/or the subject has severe acute respiratory’ distress.
In a further embodiment, the composition further comprises one or more other active agents selected including but not limited to anti-viral agents, corticosteroids, anti-coagulants, and agents that affect autophagy (including but not limited to hydroxychloroquine).
In one embodiment, the polypeptide consists of SEQ ID NO:1 and the administering comprises continuous infusion of the composition at 90 ug/kg/day for at least 4 consecutive days.
Detailed Description
As used herein, the singular fonns "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. All embodiments of any aspect of the invention can be used in combination, unless the context clearly dictates otherwise.
As used herein, the amino acid residues are abbreviated as follows: alanine (Ala; A), asparagine (Asn; N), aspartic acid (Asp; D), arginine (Arg; R), cysteine (Cys; C), glutamic acid (Giu; E), glutamine (Gin; Q), glycine (Gly; G), histidine (His; H), isoleucine (He; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Vai; V).
In one aspect, the disclosure provides methods for treating a severe acute respiratory syndrome (SARS) coronavirus infection, comprising administering to a subject with a SARS coronavirus infection a composition comprising an amount effective to treat the infection of a polypeptide consisting of at least 4 consecutive amino acids of angiotensin 1-7 (A(l-7)) [Asp-Arg-Val-Tyr-Iie-His-Pro (SEQ ID NO: 1)] or a pharmaceutically’ acceptable salt thereof, wherein the administering comprises continuous infusion of the composition for at least 7 consecutive days.
In one embodiment, the SARS coronavirus infection comprises SARS-CoV or SARS CO VID-19. In another embodiment, the SARS coronavirus infection comprises SARS COVID-19.
CO VID-19, like SARS-CoV, binds to the cell surface protein receptor, ACE2, a member of the ACE2/A(l-7)/Mas axis. SARS pathology may emerge, in part, due to the reduced ability of ACE2 to cleave Angiotensin-II (Ang-II), a pro-inflammatory, fibrotic peptide. Ang-II is a potent vasoconstrictor that can increase lung injury and lung edema, increases blood pressure, and excessive concentrations are thought to be harmful to a number of organ systems, A(l- 7) is the endogenous ligand of the Mas receptor and a member of the ACE2/A(l-7)/Mas axis. A(l-7) counteracts the effects of A-II in some situations. The methods of the invention can thus be used to treat a SARS coronavirus infection (i.e.: any SARS coronavirus that binds to cell surface protein receptor ACE2). While not being bound by a specific mechanism, the methods may provide enhanced local concentrations of A(l-7) resulting in more normal function of affected organ systems, and reduce local organ system production of Ang-II to further improve organ system function.
A( 1-7) is rapidly metabolized in the blood into fragments that are biologically active.
Thus, in various embodiments, the composition comprises one or more polypeptides consisting of the amino acid sequence:
Asp-Arg-Val-Tyr-Ile-His-Pro (SEQ ID NO: 1) A(l-7);
Asp-Arg-Val-Tyr-Ile (SEQ ID NO:2) A( 1 -5);
Arg-Val-Tyr-Ile-His-Pro (SEQ ID NO:3) A(2-7); and/or
Val-Tyr-Ile-His-Pro (SEQ ID NO:4) A(3-7).
The composition may be continuously infused by any suitable route that permits continuous infusion. In one embodiment, the administering comprises continuous intravenous infusion.
In one embodiment, the administering comprises continuous infusion of the composition for at least 8, 9, 10, 11, 12, 13, 14, or more consecutive days. In another embodiment the administering comprises continuous intravenous infusion of the polypeptide for at least 14 consecutive days.
In one embodiment, the polypeptide is administered at a concentration of between about 0.05 ug/mg (w/w) and about 500 ug/mg (w/w). In another embodiment, the polypeptide is administered at a concentration of between about 1 ug/mg (w/w) and about 100 ug/mg (w/w). In various further embodiments, the polypeptide is continuously infused at an infusion rate of at least 6.25 ng/kg/min (9 ug/kg/day); at least 25 ng/kg/min (36 ug/kg/day); at least 42 ng/kg/min (60.48 ug/kg/day), or at least 62.5 ng/kg/min (90 ug/kg/day).
As used herein, "treat" or "treating" means accomplishing one or more of the following: (a) reducing the severity or progression of the infection; (b) limiting or preventing development or progression of symptoms characteristic of the infection; (c) inhibiting worsening of symptoms characteristic of the infection; (d) limiting or preventing recurrence of symptoms in patients that were previously symptomatic for the disorder(s), (e) reducing local organ system production of angiotensin II compared to control (i.e.: subject prior to infection, or baseline determined from population of non-infected subjects), (f) reducing mortality, and/or (g) reducing length of hospital stay required.
Symptoms and features characteristic of SARS coronavirus infection that the methods may be used to treat or limit include, but are not limited to shortness of breath, reduced oxygen saturation, (SPO2), respiratory distress requiring oxygen, severe acute respiratory' distress, acute respiratory' distress syndrome (ARDS), need for hospitalization, need for
intubation or other mechanical ventilation, reduction in need for subject stay in the intensive care unit, reduction in positive end expiratory pressure (PEEP), respiratory failure, widespread inflammation and damage to multiple organ systems including the heart, kidney, liver, lungs, brain, and bone marrow; multiple organ failure, and death.
In one embodiment, the subject is a human subject that is hospitalized. In further embodiments, the subject has one or both of shortness of breath and respiratory distress requiring oxygen; and/or the subject has severe acute respiratory distress.
The subject may be any suitable subject that may be infected with a SARS coronavirus. In one embodiment the subject is a human subject. In various embodiments, the methods result in one or more of (compared to a subject with a SARS coronavirus infection who receives no treatment, and/or compared to previous symptoms of the subject prior to treatment): o Improved lung function: As used herein, ‘"improved lung function” means one or more of increased oxygenation of the blood, reduced pulmonary infiltrates, reduced dyspnea, reduced cough, reduced pain, reduced inflammation, reduced shortness of breath, reduced death rate due (at least in part) to lung complications, reduced time on ventilator, reduced time in ICU due (at least in part) to lung complications, reduced time in hospital, and/or reduced return visits to health care providers both in patient and hospitalized; o Improved bone marrow function: As used herein, “improved bone marrow function” means one or more of reduction of anemia, reduction of thrombocytopenia, reduction of lymphopenia, increases white blood cell (WBC) formation, increased lymphocyte formation, increased platelet formation, and/or increased red blood cell (RBC) production; o Improved kidney function: As used herein, “improved kidney function” means one or more of improved glomerular filtration, reduced glomerular leakages of protein, reduced pain, reduced need for dialysis, reduced proteinuria, reduced hematuria, reduced dysuria, reduced acute kidney injury, reduced renal failure, improved maintenance of glomerular filtration rate, and/or reduced inflammation; o Improved coagulation parameters. SARS coronavirus patients often have hypercoagulation so they form clots in limbs which require amputation, in the brain (stroke), and lungs as well as kidneys. As used herein, “Improved coagulation parameters means one or more of reduced embolism, reduced
embolic disease (time of onset, extent, duration), normalized coagulation, and/or reduced coagulopathy; o Improved brain function: As used herein, ‘Improved brain function” means one or more of improved cognition, reduced fuzzy brain syndrome, reduced headaches, reduced lassitude and irritability, reduced somnolence, improved attention span, reduced loss of smell and/or taste, reduced stroke, reduced inflammation, and/or reduced delirium ; and/or o Improved heart function in the subject: As used herein, “Improved brain function” means one or more of reduced incidence and/or severity of heart attack, reduced incidence and/or duration of arrhythmias, reduced congestive heart failure, improved cardiac output, reduced incidence and/or duration of vasculitis, reduced alterations in blood pressure, reduced hypertension; reduced myocarditis, reduced heart failure, improved maintenance of left ventricular function, and/or reduced inflammation.
In another embodiment, the method reduces local organ system production of angiotensin II. As noted above, Ang-II is a potent vasoconstrictor that can increase lung injury’ and lung edema, increases blood pressure, and excessive concentrations are thought to be harmful to a number of organ systems. Thus, this embodiment provides a significant treatment benefit to the subject.
In all embodiments herein, reference to the polypeptide includes salts of the polypeptide. Suitable acids which are capable of forming salts with the polypeptides include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like; and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid and the like. Suitable bases capable of forming salts with the peptides include, but are not limited to, inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally' substituted ethanol-amines (e.g., ethanolamine, diethanolamine and the like).
The polypeptide can further be derivatized to provide enhanced half-life, for example, by linking to polyethylene glycol. The peptides or salts thereof may comprise L-amino acids.
D-amino acids (which are resistant to L-amino acid-specific proteases in vivo) to convey special properties as deemed appropriate.
The compositions may comprise other components as deemed appropriate by attending medical personnel. In various embodiments, the compositions may comprise one or more (a) a lyoprotectant; (b) a surfactant; (c) a bulking agent; (d) a tonicity adjusting agent; (e) a stabilizer; (f) a preservative and/or (g) a buffer. In some embodiments, the buffer in the composition is a Tris buffer, a histidine buffer, a phosphate buffer, a citrate buffer or an acetate buffer. In one embodiment, the composition may comprise a lyoprotectant, e.g. sucrose, sorbitol or trehalose. In certain embodiments, the composition may comprise a preservative e.g. benzalkonium chloride, benzethonium, chlorohexidme, phenol, m-cresol, benzyl alcohol, methylparaben, propylparaben, chlorobutanol, o-cresol, p-cresol, chlorocresol, phenylmercuric nitrate, thimerosal, benzoic acid, and various mixtures thereof. In other embodiments, the composition may comprise a bulking agent, like glycine . In yet other embodiments, the composition may comprise a surfactant e.g., polysorbate-20, polysorbate-40, polysorbate- 60, polysorbate-65, polysorbate-80 polysorbate-85, poloxamer- 188, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trilaurate, sorbitan tristearate, sorbitan trioleaste, or a combination thereof. In one embodiment, the composition may comprise a tonicity adjusting agent, e.g., a compound that renders the formulation substantially isotonic or isoosmotic with human blood. Exemplary tonicity adjusting agents include sucrose, sorbitol, glycine, methionine, mannitol, dextrose, inositol, sodium chloride, arginine and arginine hydrochloride. In other embodiments, the composition may comprise a stabilizer, e.g., a molecule which, when combined with the polypeptide substantially prevents or reduces chemical and/or physical instability of the polypeptide in lyophilized or liquid form. Exemplary stabilizers include sucrose, sorbitol, glycine, inositol, sodium chloride, methionine, arginine, and arginine hydrochloride, paraben, and combinations of methyl paraben and propyl paraben.
Tire polypeptides may be tire sole active agent in the compositions, or the composition may further comprise one or more other active agents suitable for the desired treatment, including but not limited to anti-viral agents, corticosteroids, anti-coagulants, and agents that affect autophagy (including but not limited to hydroxychloroquine).
Example 1. A Phase 2 Randomized Double-Blinded Placebo Control (i.e. Standard of
Care) Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous
USB002 to Treat Patients with Severe Respiratory Distress due to COVID-19 Infection
LIST OF ABBREVIATIONS
A(l-7) Angiotensin 1-7
A -II Angiotensin-II
AA Gradient Alveolar-to-arterial gradient
ACE Angiotensin-converting
Enzyme
ACE2 Angiotensin-converting Enzyme 2
ADR Ad verse drug reaction
AE Adverse event
ALI Acute Lung Injury'
APACHE III Acute Physiology and Chronic Health Evaluation
III
ARDS Acute Respiratory Distress Syndrome
ARF Acute respiratory failure
ATiR Angiotensin II Receptor Type 1
AT2 Angiotensin II Receptor Type 2
AUC Area under the curve
BAL Bronchoalveolar lavage
BiPap Bilevel positive airway pressure
BMI Body Mass Index
BP Blood pressure
C Celsius
CFU-Meg Colony-forming unit - megakaryocyte
Cmax Maximum concentration
CPAP Continuous positive airway pressure
CNS Central nervous system
CO Cardiac output
COPD Chronic obstructive pulmonary disease
CRF Case report form
CT A Clinical trial agreement
CTCAE Common Tenninology Criteria for Adverse Events
CVP Central venous pressure
CVS Cardiovascular system
CXRs Chest X-Rays dL Deciliter
DLT Dose-limiting toxicity
DSMB Data Safety Monitoring Board
ECG Electrocardiogram
ECMO Extracorporeal mem brane eCRF Electronic case report form
EPO Erythropoietin
FDA Food and Drug Administration
GCP Good clinical practices
HR Heart rate
ICF Informed Consent Form
International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use
ICU Intensive care unit
IP Investigational Product
IRE Institutional Review Board
IV Intravenous
IVRS Interactive Voice Response System kg Kilogram
LIS Lung Injury Score
MAP Mean arterial pressure ug Microgram
MedDRA Medical Dictionary’ of Drag Regulatory'
Activities
MEG-1 Megakaryo blasts mg Milligrams mL Milliliter
MM Medical monitor
mm Millimeters mM Millimolar mm Hg Millimeters mercury mOsm Milliosmole
MPO Myeloperoxidase mRNA Messenger ribonucleic acid
MID Maximum tolerated dose
NCI National Cancer Institute
NDA New' Drug .Application
NF National Formulary'
NO Nitric oxide
NOAEL No-observed adverse effect level
OA Oleic acid
PaCO2 Partial arterial pressure of carbon dioxide
PAI-1 Plasminogen activator inhibitor type 1
PAO2 Partial pressure of alveolar oxygen
PBW Predicted body weight
PCWP Pulmonary capillary wedge pressure
PEEP Positive end expiratory pressure
PH Pulmonary hypertension pH Hydrogen ion concentration
PK Ph armacoki n etics
PR Pulse rate
Pt Patient
PVR Pulmonary vascular resistance
QTc QT interval corrected for heart rate
QTcB Manual correction of QT values
QTcF Automatic correction of QT values using Fridericia's
Formula
RR Respiratory rate
RRT Renal replacemen t therapy
RV pressure Right ventricular pressure SAE Serious adverse event
SaO2 Arterial oxygen saturation
SAP Statistical Analysis Plan
SBT Spontaneous breathing trial
SC Subcutaneous SD rat Sprague-Dawley rat
SD Standard deviation
SHR Spontaneously hypertensive
SOB Shortness of breath soc Standard of care SpO2 Oxygen saturation
TEAE Treatment-emergent adverse event
TF Tissue factor
TG+ Renin transgenic
TGF-1 Transforming Growth Factor 1 Vt Tidal volume
USP United States Pharmacopeia
VDI Vasopressor dependency index
VFD Ventilator-free days
VILI Ventilator-induced lung injury WBC White blood cell
WHO World Health Organization
Investigational Product: USB002
USB002 is pharmaceutically formulated Angiotensin 1-7 [A(1-7)], a non- hypertensive derivative of Angiotensin-II and is suspended in a vehicle as a sterile solution in individual vials containing 3.2 ml of USB002 (30 mg/ml) which is stable at room temperature tor 90 days.
Clinical Experience with USB002
The safety of USB002 has been demonstrated in seven clinical trials whose
indications include breast cancer and chronic kidney' disease. USB002 has also been studied in healthy volunteers. To date, 98 subjects have been treated with USB002 (referred to in studies as TXA127). Doses administered ranged from 2.5 ug/kg/day to 300 ug/kg/'day administered as a subcutaneous (SC) dose tor up to 28 days. USB002 has been well tolerated with no drug-related serious adverse events (SAEs) noted to date. A Phase 1/2 randomized, double-blinded, placebo-controlled study of USB002 given IV alone and with erythropoietin (EPO) was conducted in subjects with anemia associated with end-stage renal disease. The trial had two arms: EPO plus TXA127 at one of three doses (10, 25, or 50 ug/kg), and EPO plus placebo three times weekly, administered IV following each hemodialy sis session. No dose limiting toxicity (DLT) was observed in any dosing group. There were no differences between TXA127 and EPO in adverse events (AE) by body system. As of 01 May 2020, there were seven clinical trials listed in ClinicalTrials.gov evaluating A(l-7) for various indications.
Rationale for Clinical Trial
Due to the current pandemic, COVID-19 ieads to induced respiratory distress which progresses from SOB requiring hospitalization and supplemental oxygen by nasal cannula, high flow oxygen delivered by a mask with <15 liters/mmute of oxygen, BiPAP with a mask that delivers high pressure 100% oxygen at 5 mmHg peak inspiratory pressure, and ultimately to intubation and assisted ventilation with a respirator. With the number of COVID-19 cases in the United States since January of 2020 exceeding all other countries and the number of COVID-19 related deaths exceeding those of the Vietnam War w hich occurred over 19-years (as of May 13, 2020) and increasing, COVID- 19 pre sents an acute and urgent threat to global health security. Therapeutic interventions capable of reducing pulmonary distress would reduce the fatality rate, improve long term outcomes, and free up scarce ICU resources.
Respiratory distress in untreated COVID-19 infected patients presents as a progressive continuum from SOB to cardiopulmonary collapse and death. It is diagnosed in symptomatic patients with bilateral lung infiltrates in patients with confirmed positive tests for COVID- 19. Without supportive therapy, pulmonary distress rapidly progresses to hospitalization where supplemental oxygen can be given by nasal cannula, high-flow mask, BiPAP mask, and eventually’ intubation and assisted ventilation. Overall, the physiological damage to cells and structures of the lung can begin within hours of exposure and progress within days (Fahy 2012). The pathologic hallmarks of COVID-19-
induced pulmonary distress include neutrophilic alveolitis, hyaline membranes secondary' to protein transudation and precipitation in the airspace, microthrombi secondary to the generation of procoagulant mediators as well as endothelial and epithelial injury. For these reasons, there is considerable interest in the use of A(1 -7) to treat patients who have developed respiratory distress from COVID- 19 infection (Soto 2020, Piero 2020, NCT 04332666).
Route of Administration
USB002 or placebo will be administered IV at a continuous rate of assigned drug delivery over 96 hours in Part 1 of this protocol and over 14 days in Part 2 of the protocol. Subjects will continue to receive USB002 or placebo for the duration of the protocol- specified period of time or until there is:
1 . Sa O2 ≥ 94% on room air.
2. A perceived safety issue prevents further dose administration, or
3. Sponsor’s request to terminate the subject’s participation in the study.
Dose Regimen
IV Administration:
IJSB002 or placebo will be diluted in up to 250 ml of saline and infused continuously by a dedicated line for 96 hours in Part 1 of this protocol and for 14 days in part 2 of this protocol. New infusion set and medication will be changed based on institutional standards
Part 1 : Dose Escalation
In the Part 1 dose-escalation trial, there will be six subjects at each dose (three
USB002 and placebo; up to 24 subjects) of which 12 will receive USB002 and 12 will receive placebo. Dose escalation will follow the traditional “3+3” design for four sequential doses. If none of the three active subjects experience a DLT that is different from the placebo subjects, another three subjects will be administered USB002 at the next higher dose level and another 3 subjects will receive placebo, lire dose escalation will be performed in a randomized, double-blinded manner. However, if 1 of the three active subjects experiences a DLT different from the placebo treated subjects, three more subjects will be treated at the same USB002 dose level and another three subjects will receive
placebo. The dose escalation will continue until the maximum dose of 900 ug/kg/day is reached. The focus for the safety evaluation of each cohort will be the relative rate and type of AEs reported for the SOC plus USB002 group as compared to the SOC plus placebo group. This approach has been adopted knowing that many severe AEs will be reported due to the disease and the addition of remdesivir to the SOC
The DLT is expected to be hypotension (blood pressure [BP] < 90/60 mmHg; warranting the administration of fluid boluses or IV pressor agents). BP will be measured every7 8 hours during administration.
Infusion of USB002 or placebo will continue over 96 hrs for each subject. Dose escalation of USB002 will start at 90 ug/kg, then up to 300 ug/kg, then up to 600 ug/kg, and the maximum dose will be 900 ug/kg which is the maximum dose in the protocol for USB002 treatment of ARDS due to sepsis. Dose escalation will occur by increasing the infusion rate of 6.25 ng/kg/min (9 ug/kg/day), to 25 ng/kg/min (36 ug/kg/day), 42 ng/kg/min (60.48 ug/kg/day) and 62.5 ng/kg/min (90 ug/kg/day). The infusion rate for the SOC plus placebo will be the rate at which infusion would have occurred if the subject had randomized to SOC plus USB002.
After 96 hours the investigator will review the WBC data to determine the change from baseline. If the WBC has dropped 15% and/or lymphocytes increase by 15% after 96 hours, the treatment will be continued at the discretion ofthe investigator to Day 14.
Part 2: Preliminary Efficacy
The Part 2 preliminary efficacy determination will be randomized, double-blinded, and placebo controlled. The dose of USB002 will be the dose chosen in Part 1 ofthe protocol. Subjects will be randomized to SOC plus USB002 or SOC plus placebo (n==68 subjects/cohort, total n=136 subjects). The infusion rate of the placebo plus SOC will be the same infusion rate as the USB002 plus SOC.
Treatment Period
For Part 1 of the protocol, all subjects will receive SOC plus USB002 or SOC plus placebo for up to 96 hours: any who demonstrate a possible response to therapy will be continued to Day 14. For Part 2 of the protocol subjects will receive SOC plus USB002 or SOC plus placebo for 14 days. Infusion will be discontinued when SaOi > 94% on room air.
Vital signs will be closely monitored. Vital signs (BP, heart rate, respiration rate)
will be taken at least every 4 hours for the first 12 hrs after dosing, and every' 8 hours for the remainder of the duration of dosing with Investigational Product, or more frequently according to the institution’s standard of care.
STUDY OBJECTIVES AND PURPOSE
Primary Objective
Parts 1 and 2
To determine the safety and tolerability of USB002 in treatment of severe respiratory distress from COVID-19 infection and ascertain die existence and strength of an early efficacy signal . Part 1:
● To determine the maximum tolerated dose (MTD) of USB002 (up to 900 ug/kg/day) for 96-hours to be administered in Part 2.
Part 2
● To determine the preliminary’ efficacy of USB002 in treatment of severe respiratory' distress from COVID- 19 infection.
Study Endpoints
Part 1
Tire safety of SOC plus USB002 will focus on the rate of occurrence and severity of AEs resulting from changes in clinical monitoring criteria as compared to SOC plus placebo group:
● Cardiovascular parameters as indicated by' BP, HR, ECG, requirements for inotropes and vasopressors;
● Assessment of changes in hematological parameters, kidney’ function, and liver function (serum albumin, total and direct bilimbin, and prothrombin time).
Clinical Laboratory Evaluation (Baseline, 48-hours, 96-hours):
● Clinical chemistry'
● Hematology
● Coagulation
● LLver function
Indications of efficacy' will be assessed:
● Duration of time of unassisted breathing
● Duration of time without mechanical ventilator support
Part 2
Overall safety will be the occurrence and severity of AEs based on the clinical monitoring criteria, as in Part 1.
The primary focus of efficacy will be:
● Subjects with respiratory rate ≤ 16 breaths per minute on room air and at rest for 15 minutes on Day 28
Secondary outcomes for efficacy will be:
● All -cause mortality;
● Subjects alive and free of invasive mechanical ventilation;
● Subjects alive and discharged from the hospital;
● Subjects alive and free of respiratory failure. Respiratory failure defined based on resource utilization requiring at least 1 of the following:
● Endotrachealintubation and mechanical ventilation
● Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced, nasal cannula, at flow rates > 20 L/min with fraction of delivered oxygen < 0.5)
● Noninvasive positive pressure ventilation
● Extracorporeal membrane oxygenation (ECMO)
● Change in the WHO nine-point ordinal scale of clinical status;
● Recovery landmarks: time to meeting weaning criteria, 30-minute spontaneous breathing trial and time to discontinuation of ventilatory assistance, if applicable.
The WHO nine-point ordinal scale of clinical improvement (OSCI score) is defined as the following:
1 . Uninfected: No clinical or virological evidence of infection
2. Ambulatory: No limitation of activities
3. Ambulatory: Limitation of activities
4. Hospitalized; mild disease: Hospitalized, no oxygen therapy
5. Hospitalized; mild disease: Oxygen by mask or nasal prongs
6. Hospitalized; severe disease: Non-invasive ventilation or high-flow oxygen
7. Hospitalized; severe disease: Intubation and mechanical ventilation
8. Hospitalized; severe disease: Ventilation and additional organ support - pressors, RRT, ECMO
9. Dead: Death
Additional Outcomes
● Changes in Sp O2 (measured by pulseoximetry)
● Changes in positive end expiratory pressure (PEEP)
● Duration assisted ventilation
● Duration of time of unassisted breathing
● Duration of time without mechanical ventilator support
STUDY DESIGN
Part 1
Dose-escalation will be randomized, double-blinded, placebo-controlled study performed in up to 24 subjects, up to six subjects (in addition to SOC, three will receive USB002 and three will receive placebo) in each of 4 doses. Subjects will receive a continuous IV infusion of USB002 for 96-hours followed by an additional 24-hours to assess safety. For subjects who show signs of a possible response as indicated by a decrease in WBC from baseline of 15% and/or increase in lymphocytes by 15%, the investigator may continue therapy until Day 14. Infusion will be discontinued if Sa O2 ≥ 94% on room air.
The decision to dose-escalate, de-escalate, or increase the number of subjects in a Group to further examine safety variables will be made by a Data Safety Monitoring Board (DSMB). Minutes will be recorded at the decision meetings and circulated for final approval before being placed on file. The dose escalation will use the traditional 3-1-3 design to assess dose-response as described in section 1 .4.3 Dose Regimen.
Early and regular assessment of the progress and safety will be conducted by the DSMB. If there is any concern, a delay to future enrollment may be instituted at the discretion of the DSMB, who will have access to study' data via the electronic case report forms (eCRFs).
If there is toxicity at the lowest level (6.25 ng/kg/min; 90 ug/day), the option
for de- escalation will be discussed and determined by the DSMB.
If a subject withdraws or is withdrawn for reasons oilier than DLT prior to completing the 48-hr treatment period, the subject will not be replaced.
Toxicity will be graded according to the NCI-CTCAE Version 5.0 criteria. Limiting toxicities will be considered as any SAE or Grade 3 to 5 toxicity judged to be probably or definitely related to USB002 or any of the predetermined study specific criteria, as determined by the DSMB.
Definition of a cardiovascular DLT: Systolic pressure, diastolic pressure, heart rate, and inotropes and doses thereof will be recorded just prior to administration of study drug, to establish an appropriate baseline in the context of the individual patient's situation. A reduction of: 15% in BP or HR in conjunction with other symptoms and/or signs will be flagged as a potential DLT to be reviewed by the Medical Monitor (MM) and/or DSMB.
Part 2
Part 2, preliminary efficacy assessment will be performed in a randomized, double- blinded, placebo-controlled study which will begin enrolling after Part 1 is complete through Day 28. In Part 2, subjects will continuously receive for 14 days the dose of USB002 selected in Part 1 . Clinical status of subjects will be evaluated once weekly using the nine-level ordinal scale (WHO Master Protocol R&D Blueprint, version 2, February 18, 2020; NCT04292899). Subject participation in Part 2 will terminate on Day 60. Follow- up for the assessment of any AEs and mortality to Day 60 regardless of treatment or hospitalization status. Infusion will be discontinued before 14 days if Sa O2 > 94% on room air.
Toxicity will be graded according to the NCI-CTCAE Version 5.0 criteria. Limiting toxicities will be considered as any SAE or Grade 3 to 5 toxicity judged to be probably or definitely related to USB002 or any of the predetermined study specific criteria, as determined by the DMSB.
Description of Treatment(s); Drug Packaging and Labeling
USB002 is formulated as a sterile, preservative-free, non-pyrogenic solution for injection. Formulated solution for injection consists of the following (Table 1):
The parenteral formulation is produced as a pH buffered solution, adjusted for the proper osmolality with the addition of 4% mannitol to provide a final osmolality of 295-415 mOsm for the dosing concentrations of A(l-7). The product is packaged in a 30 mg/ml, single- use, stoppered vial with a 3.2-mL fill. Tire individual components used to manufacture the drug product are commonly used in other parenteral drug products.
Sterilization of USB002 is achieved via 0.22-micron filtration of the final bulk solution into the appropriate number of vials filled under aseptic conditions.
Placebo will be the same formulation as USB002 without angiotensin 1-7.
Investigational Product Administration
The investigational product (IP) will be held secure in the site pharmacy, where it will be prepared for infusion and provided to the study staff for subject infusion/injection. The IP will be provided to the study staff indicating the date, subject ID#, and dose.
Dosage concentrations are standardized so that a 10-pL volume of solution will be dispensed per kilogram of subject body mass, based on the subject’s baseline weight.
Preparation for Administration
USB002 is a single-use parenteral product, supplied in sterile, pre-mixed, ready-to- use 3.2-mL vials. A new, unused vial should be used for each dose. Used vials should be retained for accountability monitoring by the Sponsor.
Invert the vial gently several times before use, to ensure uniformity of the solution prior to withdrawing the amount required based on the subject s weight. Maintain aseptic technique while handling USB002, and inspect for particulate matter and discoloration prior to administration whenever the solution and container permit. Do not use the study drug if contamination is suspected .
Withdraw the required volume from the vial (via appropriate gauge needle and syringe) and make up the volume to 5 mL with sterile saline. Cap the needle for delivery to the study staff. Labels to be placed on the syringe will be provided for completion to
identify the subject #, dose #, and time of preparation. Tire drug must be used (infusion or SC administration completed) within 36 hours of preparation.
For IV administration, USB002 should not be administered at the same time with other medications in the line and in some instances may' require a dedicated line however, USB002 can be administered with the following:
● Water for injection, USP
● Sodium Chloride (0.9%) Injection, USP
● Dextrose (5%) Injection USP
● Dextrose (5%) in Sodium Chloride (0.9%) Injection, USP
● Dextrose in Ringers Lactate Injection, USP
● Lactated Ringers Injection, USP
As far as possible, for a period of 90 minutes after initiation ofUSB002 infusion the patient should not be scheduled for any procedures, administered any medications that may reduce B P or transported out of the ward or ICU for any reason.
Study Duration and Tria! Periods
Subjects will be enrolled to the trial once they are diagnosed with COVID-19 and pulmonary distress requiring supplemental oxygen, consent has been obtained from the subjects or their legal representative and eligibility' has been confirmed. Baseline laboratory' assessments will be obtained, if not already completed prior to subject consent. Baseline data will include time of admission to hospital, ICU, and time of supplemental oxygen therapy, nasal high-flow oxygen therapy, non-invasive mechanical ventilation or mechanical ventilator via intubation initiation. Registration will be performed by the Study Coordinator, the drug will be requested from the pharmacy, and dosing will begin within 6 hours (study Dav 1).
PATIENT SELECTION CRITERIA
Inclusion Criteria
1 . Prior to any study-related procedures Informed Consent must be obtained from tire patient or from the legal representative;
2. Women of childbearing po tential who use highly effective me thods of birth control
defined as those, alone or in combination, that result in a low failure rate when used consistently and correctly;
3. Patients with a confirmed severe diagnosis of COVID-19 by FDA-approved testing within 1 week of enrollment. Severe disease is defined as patients with an oxygen saturation (SaO2) < 94% on room air or requiring supplemental oxygen or requiring invasive mechanical ventilation, or requiring ECMO;
4. Patients who are admitted to a hospital and under the care or consultation of a licensed clinician (skilled in the diagnosis and management of patients with potentially life-threatening illness and the ability to recognize and manage medication-related AE): Patients for whom use of an IV agent is clinically appropriate;
5. Age 18 or greater (no upper limit); males and females;
6. Subjects who receive SOC appropriate to treat respiratory' distress associated with COVID- 19 infection including remdesivir, dosed as per the FDA approved Emergency Use Authorization Instructions for Use, anticoagulants, dexamethasone or other medications found to benefit subjects with COVID- 19 induced pulmonary distress as per the recommendation of FDA.
Exclusion Criteria
1. Terminally ill patients due to underlying cardiac, cancer or severe debilitating neurological disease including coma;
2. Pregnant and lactating women;
3. Patients who are imminently being discharged from the hospital due to medical improvement;
4. Interstitial lung disease, pulmonary embolism, pneumothorax, cerebrovascular accident, cardiac valve pathology;
5. QTcF > 450 ms;
6. History of hypotension;
7. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times upper limit of normal;
8. Participating in any other clinical trial of an experimental treatment for COVID-19.
ASSESSMENT OF EFFICACY
The primary measure of efficacy is:
● Subjects with respiratory rate ≤ 16 breaths per minute on room air and at rest for 15 minutes on Day 28.
Secondary outcomes for efficacy will be:
● All -cause mortality;
● Subjects alive and free of invasive mechanical ventilation; ● Subjects alive and discharged from the hospital;
● Subjects alive and free of respiratory failure. Respiratory failure defined based on resource utilization requiring at least 1 of the following:
● Endotracheal intubation and mechanical ventilation;
● Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates > 20 L/min with fraction of delivered oxygen < 0.5);
● Noninvasive positive pressure ventilation;
● Extracorporeal membrane oxygenation (ECMO);
● Change in the WHO nine-point ordinal scale of clinical improvement;
● Recovery landmarks: time to meeting weaning criteria, 30-minute spontaneous breathing trial and time to discontinuation of ventilatory assistance, if applicable.
Adverse Events (AE)
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether considered causally related to the product. An undesirable medical condition can be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver), or the abnormal results of an investigation (e.g., laboratory findings, ECG). In clinical studies, an AE can include an undesirable medical condition occurring at any time, including run- in or washout periods, even if no study treatment has been administered. Treatment- emergent sepsis-related symptoms and events (i.e., not present at baseline or worsened in severity following start of treatment) should be reported as AEs.
Serious Adverse Events (SAE)
A SAE is an AE occurring during any study phase (i.e., run-in, treatment, washout, follow'- up), and at any dose of the IP, comparator, or placebo, that meets one or more of the following criteria:
● Results in death;
● Is immediately life-threatening;
● Requires in-patient hospitalization or prolongation of existing hospitalization;
● Results m persistent or significant disability or incapacity;
● Is a congenital abnormality or birth defect;
● Is an important medical event that may jeopardize the patient or may require medical intervention to prevent one of the outcomes listed above.
STATISTICAL METHODS
Detailed statistical analysis information will be provided separately in the SAP which will be signed off prior to database lock; Part 1 and Part 2 will have separate SAPs as the research question to be addressed is different for the two Parts. The focus for Part 1 will be reviewing the safety and possible efficacy signals for the escalating dose for the SOC plus USB002 subjects as compared to the SOC plus placebo group, while for Part 2 the interest is in the comparison of the efficacy outcomes of the randomized groups (i.e. SOC plus USB002 vs. SOC plus placebo). Any deviations to the planned analyses specified within the SAP will be justified in writing and presented within the final clinical study report.
In Part 1, the data summaries, which will be supported with by-subject listings, will focus on the dose group for SOC phis USB002 as compared to the SOC plus placebo as well as time in trial. Any subjects who are allowed to re-initiate therapy will be highlighted and presented separately.
Part 2 efficacy assessments will focus on comparing the endpoints for the two treatment groups for a signal of efficacy including: subjects with respiratory rate ≤ 16 breaths per minute on room air and at rest for 15 minutes on Day 28, all-cause mortality, time without mechanical ventilation, subjects discharge alive, subjects free of respiratory failure, responders according the change in clinical status using a 9-point ordinal scale (WHO Master Protocol R&D Blueprint, version 2, February 18, 2020, NCT04292899). Data relating to efficacy response will be listed and summarized by dose cohort and time point, as appropriate. On each measurement day, the worst score from the previous day of measure will be recorded.
Efficacy Analysis
The primary outcome, proportion of subjects with respiratory rate < 16 breaths per minute on room air and at rest for 15 minutes at Day 28, will be compared between the two treatment groups using Fisher’s exact test. Subjects who die or on ventilator at the time of the Day 28 assessment will be considered as a failure, and subjects who are alive and discharged from hospital by Day 28 will be considered as a success for this outcome, A logistic regression analysis will also be performed to adjust for the baseline covariates: age baseline severity, and comorbidity.
The secondary outcomes that are binary, e.g. subjects alive and free of invasive mechanical ventilation, the proportion will be compared be compared using Fisher’s exact test. As in the primary outcome analysis, subjects who die on or before the Day 28 assessment will be considered as failure for these outcomes. For outcomes related to time to event, they will be analyzed using a Cox proportional hazards model incorporating the same baseline covariates as in the primary outcome analysis; summary statistics will be presented with survival curves. The proportion of subjects who remained free of respiratory failure will be analyzed with logistic regression as will the secondary outcome change in the WHO scale by one category.
All other outcomes will be presented descriptively.
REFERENCES
I .Chen YJ, DeMets DL, and Gordon Lan K. Increasing the sample size when the unblended interim result is promising. Statistics in Medicine; 2004; 23(7): 102.3-1038. 2. Donoghue M. Heart block, ventricular tachycardia, and sudden death in ACE2. transgenic mice with downregulated connexins. Journal of Molecular and Cellular Cardiology. Academic Press; 2003 Sep 1 ;35(9): 1043-53.
3. Fahy RJ, Lichtenberger F, McKeegan CB, Nuovo GJ, Marsh CB, Wewers MD. The Acute Respiratory' Distress Syndrome. American Journal of Respiratory Ceil and Molecular Biology. American Thoracic Society; 2012 Dec 20;28(4):499-503.
4. Fleming I, Kohlstedt K, Busse R. New fACEs to the Renin-Angiotensin System.
Physiology; 2005 Apr 1 ;20(2):91-5.
5. Flemming A. Unravelling SA RS lethality. Nat Rev Drag Discov. Nature Publishing
Group; 2005 Sep 1 ;4(9):718- 8.
6. Imai Y, Kuba K, Penninger JM. The discover}' of angiotensin converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol; 2008; May 93(5): 543-548.
7. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. Nature Publishing Group; 2005 Jul 7;436(7047): 112—6.
S.Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of Angiotensin -Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors.
Hypertension. Lippincott Williams & Wilkins; 2004 May l;43(5):970-6.
9.Kostenis E, Milligan G, Christopoulos A, et al. G-Protein-Coupled Receptor Mas Is a
Physiological Antagonist of the Angiotensin II Type 1 Receptor. Circulation.
Lippincot Williams & Wilkins; 2005 Apr 12;111(14): 1806-13.
10. Lui Y, Yang Y, Zhang C et al. Clinical and biochemical indexes from 2019- nCoV infected patients linked to viral loads and lung injury'. Science China Life Sciences March 2020 63(3); 364-374
1 1 . NCT 04292899 Study to Evaluate the Safety and Antiviral Activity of Remdesivir(GS- 5734) in Participants with Severe Coronaviraus Disease (COVID- 19)
12. NCT 04332666 Agniotensin-(1,7) Treatment in COVID-19: the ATCO Trial
13. Nehme A, Zouein FA, et al. An update on the tissue renin angiotensin system and its role in physiology and pathophysiology. J. Cardiovas Dev Dis 2019; 6:14-30.
14. Papinska AM, Mordwinkin NM, Meeks CJ, Jadhav SS, Rodgers KE. Angiotensin-(1- 7) administration benefits cardiac, renal and progenitor cell function in db/dbmice. Br J Pharmacol [Internet], 2015 Jul 30;172(18):4443-53.
15. Papinska AM, Rodgers KE. Long-Term Administration of Angiotensin (1-7) to db/db Mice Reduces Oxidative Stress Damage in the Kidneys and Prevents Renal Dysfunction. Oxid Med Cell Longev. Hindawi; 2018;2018: 1841046-10.
16. Peiro C and Moncada S. Substituting Angiotensm-(l-7) to Prevent Lung Damage in SARS-CoV2 Infection? 10.1 161/Circulationaha, 120.0447297
17. Reddy R, Asante I, Liu P, Liebier J, Borok Z, Rodgers, et al. Circulating angiotensin peptide levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study. PLOS ONE: doi,org/10.137/joumal.pone. 0213096; March 7, 2019.
18. Rodgers KE, Oliver J, & diZerega GS. Phase I/II dose escalation study of Angiotensin 1-7 [A( 1-7)] administered before and after chemotherapy in patients with newly- diagnosed breast cancer. Can Chemother Pharmacol May 2006 57(5); 559-568.
19. Shenoy V, Ferreira AJ, Qi Y, et al. The angiotensin-converting enzyme 2/angiogenesis-(l-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary' hypertension. American Journal of Respiratory’ and Critical Care Medicine. American Thoracic Society; 2010 Oct 15;182(8): 1065— 7:2.
20. Soto M. diZerega G, Rodgers KE. Countermeasure & therapeutic: A(l-7) to Treat Acute Respiratory Distress Syndrome due to CO VID- 19 Infection. J Rennin- Angiotensin- Aldosterone System, in review.
21 . Soto M, Gaffney KJ, Rodgers KE. Improving the Innate Immune Response in Diabetes by Modifying the Renin Angiotensin System. Front Immunol. Frontiers; 2019; 10:2885.
22. Walther T, Kuebler W, Berlin CU. Use of an ang-(l-7) receptor agonist m acute lung injury. 2011 Nov 17.
23. WHO Master Protocol R&D Bluep, version 2, 2020
24. Yamada K, Iyer SN, Chappell MC, Ganten D, & Ferrario CM. Converting enzyme determines plasma clearance of angiotensin-fl -7). Hypertension; 1997 Sep; 32(3): 496-502.
25.Yamazato Y, Ferreira AJ, Hong K-H, Sriramula S, Francis J, Yamazato M, et al. Prevention of Pulmonary Hypertension by Angiotensin-Converting Enzyme 2 Gene Transfer. Hyertension. Lippincott Williams & Wilkins; 2009 Aug 1;54(2):365-71.
26.Zambel1i V, Bellani G, Borsa R, Pozzi F, Grass! A, Scanziani M, et al. Angiotensin-(1- 7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory'- Distress Syndrome. ICMx. SpringerOpen; 2015 Dec 1;3(1): 1- 17.
27. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. Nature Publishing Group; 2.020 Mar;579(7798):270-3.
Example 2
Part 1 of the study detailed in Example 1 was carried out on patients having severe respiratory' distress from COVID-19 infection and requiring mechanical ventilation or noninvasive ventilation support to survive. To date, the number of patients is 6. with 3 on USB002 and 3 on placebo.
The first dose was 90 ug/kg infused intravenously over 24-hours for 4-days (96 hrs). Thus, each day the study subject received 90 ug/kg in a constant infusion. The placebo was the vehicle (essentially saline) the USB002 was dissolved in. Dose escalation is ongoing, and
results from the first 6 subjects at the first dose is provided. All subjects were also provided standard of care therapy (antiviral medication, oxygen ventilation, IV crystalloid support, anti-inflammatory medication).
MV mechanical ventilation (respirator and intubation), NIV noninvasive ventilation
(usually high oxygen flow mask), The data in Table 1 is believed to show that subjects receiving USB002 treatment had significantly improved survival, improved clinical status as measure by OSCI score, improvement in spontaneous ventilation, and/or reduction in C -reactive protein levels in their blood relative to placebo treated subjects, over the course the study, and it is believed that such therapeutic benefits will be maintained or increase with longer term treatment. Reduction in serum CRP (measure of overall body inflammation) is a major indicator of improved organ function. CO VID-19 effects most organs, not just lungs.
Claims
1 . A method for treating a severe acute respiratory syndrome (SARS) coronavirus infection, comprising administering to a subject with a SARS coronavirus infection a composition comprising an amount effective to treat the infection of a polypeptide consisting of at least 4 consecutive amino acids of angiotensin 1-7 (A(l-7)) [Asp-Arg-Val-Tyr-Ile-His- Pro (SEQ ID NO: 1)] or a pharmaceutically acceptable salt thereof, wherein the administering comprises continuous infusion of the composition for at least 4. 5, 6, or 7 consecutive days.
2. The method of claim 1, wherein the SARS coronavirus infection comprises SARS- CoV or SARS COVID-19.
3. The method of claim 1, wherein the SARS coronavirus infection comprises SARS COVID-19
4. The method of any one of claims 1-3, wherein the composition comprises one or more polypeptides consisting of the amino acid sequence:
Asp-Arg-Val-Tyr-Ile-His-Pro (SEQ ID NO: 1) A(l-7); Asp-Arg-Val-Tyr-Ile (SEQ ID NOV) A(l-5);
Arg-Val-Tyr-Ile-His-Pro (SEQ ID NOV) A(2-7); and/or Val-Tyr-ile-His-Pro (SEQ ID NO:4) A(3-7).
5. The method of any one of claims 1-3, wherein the polypeptide consists of SEQ ID NO:1.
6. The method of any one of claims 1-3, wherein the polypeptide consists of SEQ ID NOV.
7. The method of any one of claims 1-3, wherein the polypeptide consists of SEQ ID
NOV.
8. The method of any one of claims 1-3, wherein the polypeptide consists of SEQ ID NO:4.
9. The method of any one of claims 1-8, wherein the administering comprises continuous intravenous infusion
10. The method of any one of claims 1-9, wherein the administering comprises continuous infusion of the composition for at least 8, 9, 10, 11, 12, 13, 14, or more consecutive days.
11. The method of any one of claims 1-9, wherein the administering comprises continuous intravenous infusion of the composition for at least 14 consecutive days.
12. The method of any one of claims 1-1 1, wherein the polypeptide is administered at a concentration of between about 0.05 ug/mg (w/w) and about 500 ug/mg (w/w).
13. The method of any one of claims 1-1 1, wherein the polypeptide is administered at a concentration of between about 1 ug/mg (w/w) and about 100 ug/mg (w/w).
14. The method of any one of claims 1-11, wherein the polypeptide is continuously infused at an infusion rate of at least 6.25 ng/kg/min (9 ug/kg/day); at least 25 ng/kg/min (36 ug/kg/day); at least 42 ng/kg/min (60.48 ug/kg/day), or at least 62.5 ng/kg/min (90 ug/kg/day).
15. The method of any one of claims 1-14, wherein the subject is a human subject.
16. The method of any one of claims 1-15, wherein the method improves lung function.
17. Hie method of any one of claims 1-16, wherein the method improves bone marrow function.
18. The method of any one of claims 1-17, wherein the method improves kidney function.
19. The method of any one of claims 1-18, wherein the method improves coagulation parameters.
20. The method of any one of claims 1-19, wherein the method improves brain function .
21. The method of any one of claims 1-20, wherein the method improves heart function.
22. The method of any one of claims 1-21, wherein the method reduces local organ system production of angiotensin II.
23. The method of any one of claims 1-22, wherein the subject is a human subject that is hospitalized.
24 The method of any one of claims 1 -23, wherein the subject has one or both of shortness of breath and respiratory distress requiring oxygen.
25. The method of any one of claims 1-24, wherein the subject has severe acute respirator}' distress.
26. The method of any one of claims 1-25, wherein the composition further comprises one or more other active agents selected including but not limited to anti-viral agents, corticosteroids, anti -coagulants, and agents that affect autophagy (including but not limited to hydroxychloroquine) .
27. The method of claim 1, wherein the polypeptide consists of SEQ ID NO: 1 and wherein the administering comprises continuous infusion of the composition at 90 ug/kg/day for at least 4 consecutive days.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063108272P | 2020-10-30 | 2020-10-30 | |
US63/108,272 | 2020-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022094025A1 true WO2022094025A1 (en) | 2022-05-05 |
Family
ID=78725677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/056974 WO2022094025A1 (en) | 2020-10-30 | 2021-10-28 | Angiotensin-1-7 for the treatment of covid-19 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022094025A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4371556A1 (en) * | 2022-11-15 | 2024-05-22 | Explicat Pharma GmbH | Angiotensin(1-7) pharmaceutical compositions for inhalation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2163259A1 (en) * | 2008-09-12 | 2010-03-17 | Charité-Universitätsmedizin Berlin (Charité) | Use of an Ang-(1-7) receptor agonist in acute lung injury |
WO2021183863A1 (en) * | 2020-03-13 | 2021-09-16 | Constant Therapeutics Llc | Methods and compositions for treatment of coronavirus infection |
-
2021
- 2021-10-28 WO PCT/US2021/056974 patent/WO2022094025A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2163259A1 (en) * | 2008-09-12 | 2010-03-17 | Charité-Universitätsmedizin Berlin (Charité) | Use of an Ang-(1-7) receptor agonist in acute lung injury |
WO2021183863A1 (en) * | 2020-03-13 | 2021-09-16 | Constant Therapeutics Llc | Methods and compositions for treatment of coronavirus infection |
Non-Patent Citations (37)
Title |
---|
ANONYMOUS: "History of Changes for Study: NCT04332666 Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (ATCO)", CLINICALTRIALS.GOV, 18 August 2020 (2020-08-18), pages 1 - 6, XP055883075, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/history/NCT04332666?V_3=View#StudyPageTop> [retrieved on 20220124] * |
ANONYMOUS: "History of Changes for Study: NCT04570501 Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients", CLINICALTRIALS.GOV, 28 September 2020 (2020-09-28), pages 1 - 4, XP055883154, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT04570501?V_1=View> [retrieved on 20220124] * |
ANONYMOUS: "Treatment of Angiotensin Peptide (1-7) for COVID-19", CLINICALTRIALS.GOV, 15 May 2020 (2020-05-15), pages 1 - 5, XP055883141, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/history/NCT04375124?V_3=View#StudyPageTop> [retrieved on 20220124] * |
CHEN YJDEMETS DLGORDON LAN K: "Increasing the sample size when the unblended interim result is promising", STATISTICS IN MEDICINE, vol. 23, no. 7, 2004, pages 1023 - 1038 |
DONOGHUE M: "Journal of Molecular and Cellular Cardiology", vol. 35, 1 September 2003, ACADEMIC PRESS, article "Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins", pages: 1043 - 53 |
FABRIZIO PUCCI ET AL: "Modeling the molecular impact of SARS-CoV-2 infection on the renin-angiotensin system", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 1 August 2020 (2020-08-01), XP081732463 * |
FAHY RJLICHTENBERGER FMCKEEGAN CBNUOVO GJMARSH CBWEWERS MD: "American Journal of Respiratory Cell and Molecular Biology", vol. 28, 20 December 2012, AMERICAN THORACIC SOCIETY, article "The Acute Respiratory Distress Syndrome", pages: 499 - 503 |
FLEMING IKOHLSTEDT KBUSSE R: "New fACEs to the Renin-Angiotensin System", PHYSIOLOGY, vol. 20, no. 2, 1 April 2005 (2005-04-01), pages 91 - 5 |
FLEMMING A.: "Nat Rev Drug Discov", vol. 4, 1 September 2005, NATURE PUBLISHING GROUP, article "Unravelling SARS lethality", pages: 718 - 8 |
GUL RUKHSANA ET AL: "Renin-angiotensin system at the interface of COVID-19 infection", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 890, 18 October 2020 (2020-10-18), XP086411587, ISSN: 0014-2999, [retrieved on 20201018], DOI: 10.1016/J.EJPHAR.2020.173656 * |
IMANPOUR HAMED ET AL: "Angiotensin 1-7: A Novel Strategy in COVID-19 Treatment Letter to Editor", ADV PHARM BULL, 1 January 2020 (2020-01-01), pages 488 - 489, XP055853771, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539308/pdf/apb-10-488.pdf> [retrieved on 20211021] * |
ISHIYAMA Y, GALLAGHER PE, AVERILL DB: "Hypertension", vol. 43, 1 May 2004, LIPPINCOTT WILLIAMS & WILKINS, article "Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors", pages: 970 - 6 |
KOSTENIS EMILLIGAN GCHRISTOPOULOS A ET AL.: "Circulation", vol. 111, 12 April 2005, LIPPINCOTT WILLIAMS & WILKINS, article "G-Protein-Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor", pages: 1806 - 13 |
LMAI YKUBAKPENNINGER JM: "The discovery of angiotensin converting enzyme 2 and its role in acute lung injury in mice", EXP PHYSIOL, vol. 93, no. 5, May 2008 (2008-05-01), pages 543 - 548 |
LUI YYANG YZHANG C ET AL., CLINICAL AND BIOCHEMICAL INDEXES FROM 2019-NCOV INFECTED PATIENTS LINKED TO VIRAL LOADS AND LUNG INJURY SCIENCE CHINA LIFE SCIENCES, vol. 63, no. 3, March 2020 (2020-03-01), pages 364 - 374 |
MAGALHAES GISELLE SANTOS ET AL: "Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection", FRONTIERS IN PHYSIOLOGY, vol. 11, 19 June 2020 (2020-06-19), CH, pages 730, XP055883079, ISSN: 1664-042X, DOI: 10.3389/fphys.2020.00730 * |
MERY GEOFFROY ET AL: "COVID-19: Underlying Adipokine Storm and Angiotensin 1-7 Umbrella", FRONTIERS IN IMMUNOLOGY, vol. 11, 1 January 2020 (2020-01-01), pages 1714, XP055808179, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385229/pdf/fimmu-11-01714.pdf> DOI: 10.3389/fimmu.2020.01714 * |
NCT 04292899 STUDY TO EVALUATE THE SAFETY AND ANTIVIRAL ACTIVITY OF REMDESIVIR(GS- 5734) IN PARTICIPANTS WITH SEVERE CORONAVIRAUS DISEASE (COVID-19 |
NCT 04332666 AGNIOTENSIN-(1,7) TREATMENT IN COVID-19: THE ATCO TRIAL |
NEHME AZOUEIN FA ET AL.: "An update on the tissue renin angiotensin system and its role in physiology and pathophysiology", J. CARDIOVAS DEV DIS, vol. 6, 2019, pages 14 - 30 |
PAPINSKA AMMORDWINKIN NMMEEKS CJJADHAV SSRODGERS KE: "Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db/dbmice", BR J PHARMACOL [INTERNET, vol. 172, no. 18, 30 July 2015 (2015-07-30), pages 4443 - 53, XP071110438, DOI: 10.1111/bph.13225 |
PAPINSKA AMRODGERS KE: "Long-Term Administration of Angiotensin (1-7) to db/db Mice Reduces Oxidative Stress Damage in the Kidneys and Prevents Renal Dysfunction. Oxid Med Cell Longev", HINDAWI, vol. 2018, 2018, pages 1841046 - 10 |
PEIRO CMONCADA S: "Substituting Angiotensin-( 1-7) to Prevent Lung Damage in SARS-CoV2 Infection?", CIRCULATIONAHA |
PEIRÓ CONCEPCIÓN ET AL: "Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection?", CIRCULATION, vol. 141, no. 21, 3 April 2020 (2020-04-03), US, pages 1665 - 1666, XP055883053, ISSN: 0009-7322, Retrieved from the Internet <URL:http://dx.doi.org/10.1161/CIRCULATIONAHA.120.047297> DOI: 10.1161/CIRCULATIONAHA.120.047297 * |
REDDY RASANTE ILIU PLIEBLER JBOROK ZRODGERS ET AL.: "Circulating angiotensin peptide levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study", PLOS ONE, 7 March 2019 (2019-03-07) |
RODGERS KEOLIVER JDIZEREGA GS: "Phase IIII dose escalation study of Angiotensin 1-7 [A(I-7)1 administered before and after chemotherapy in patients with newly diagnosed breast cancer", CAN CHEMOTHER PHARMACOL, vol. 57, no. 5, May 2006 (2006-05-01), pages 559 - 568 |
SHENOY VFERREIRA AJQI Y ET AL.: "American Journal of Respiratory and Critical Care Medicine", vol. 182, 15 October 2010, AMERICAN THORACIC SOCIETY, article "The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension", pages: 1065 - 72 |
SOTO MDIZEREGA GRODGERS KE: "Countermeasure & therapeutic: A(1-7) to Treat Acute Respiratory Distress Syndrome due to COVID-19 Infection", J RENNIN-ANGIOTENSIN-ALDOSTERONE SYSTEM |
SOTO MGAFFNEY KJRODGERS KE: "Improving the Innate Immune Response in Diabetes by Modifying the Renin Angiotensin System", FRONT IMMUNOL. FRONTIERS, vol. 10, 2019, pages 2885 |
STEFANIE SUPÉ ET AL: "Therapeutic time window for angiotensin-(1-7) in acute lung injury", BRITISH JOURNAL OF PHARMACOLOGY, WILEY-BLACKWELL, UK, vol. 173, no. 10, 21 March 2016 (2016-03-21), pages 1618 - 1628, XP071096083, ISSN: 0007-1188, DOI: 10.1111/BPH.13462 * |
WALTHER TKUEBLER WBERLIN CU, USE OF AN ANG-(L-7) RECEPTOR AGONIST IN ACUTE LUNG INJURY, 17 November 2011 (2011-11-17) |
WHO MASTER PROTOCOL R&D BLUEP, 2020 |
YAMADA KIYER SNCHAPPELL MCGANTEN DFERRARIO CM: "Converting enzyme determines plasma clearance of angiotetisin-(1-7", HYPERTENSION, vol. 32, no. 3, September 1997 (1997-09-01), pages 496 - 502 |
YAMAZATO Y, FERREIRA AJ, HONG K-H, SRIRAMULA S, FRANCIS J. YAMAZATO M: "Hyertension", vol. 54, 1 August 2009, LIPPINCOTT WILLIAMS & WILKINS, article "Prevention of Pulmonary Hypertension by Angiotensin-Converting Enzyme 2 Gene Transfer", pages: 365 - 71 |
ZAMBELLI VANESSA ET AL: "Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome", INTENSIVE CARE MEDICINE EXPERIMENTAL, vol. 3, no. 1, 1 December 2015 (2015-12-01), XP055883213, Retrieved from the Internet <URL:https://icm-experimental.springeropen.com/track/pdf/10.1186/s40635-015-0044-3.pdf> DOI: 10.1186/s40635-015-0044-3 * |
ZAMBELLI VBELLANI GBORSA RPOZZI FGRASSI ASCANZIANI M ET AL.: "ICMx", vol. 3, 1 December 2015, SPRINGEROPEN, article "Angiotensin-( 1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome", pages: 1 - 17 |
ZHOU PYANG X-LWANG X-G ET AL.: "Nature", vol. 579, March 2020, NATURE PUBLISHING GROUP, article "A pneumonia outbreak associated with a new coronavirus of probable bat origin", pages: 270 - 3 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4371556A1 (en) * | 2022-11-15 | 2024-05-22 | Explicat Pharma GmbH | Angiotensin(1-7) pharmaceutical compositions for inhalation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020256322B2 (en) | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency | |
AU2020203183B2 (en) | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency | |
HUE033949T2 (en) | Sodium chloride solution for drug reconstitution or dilution | |
WO2022094025A1 (en) | Angiotensin-1-7 for the treatment of covid-19 | |
ES2913946T3 (en) | Peptide and its use in the treatment of inflammatory disorders | |
US20230293640A1 (en) | Compounds for the treatment of endotheliitis in context of virally caused diseases | |
US20220008499A1 (en) | Compounds, compositions and methods for treating sepsis | |
WO2022207918A1 (en) | COVID-19 Therapy | |
US20230173030A1 (en) | Vasoactive intestinal peptide fusion proteins for the treatment of covid-19 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21811630 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21811630 Country of ref document: EP Kind code of ref document: A1 |